Abeona Therapeutics Expands Access to ZEVASKYN Gene Therapy
Abeona Therapeutics Expands Access to ZEVASKYN Gene Therapy
Abeona Therapeutics Inc. is thrilled to announce a significant milestone in the realm of gene therapy: the availability of ZEVASKYN (prademagene zamikeracel) at Lucile Packard Children’s Hospital Stanford. This pioneering treatment marks a transformative step for patients suffering from recessive dystrophic epidermolysis bullosa (RDEB), a rare and severe skin condition.
What is ZEVASKYN?
ZEVASKYN is the first and only autologous cell sheet-based gene therapy approved to treat RDEB. This innovative therapy involves taking a patient’s own skin cells and modifying them to produce functional type VII collagen, which is essential for skin integrity. The treatment aims to heal wounds and alleviate pain associated with this challenging disorder, offering hope for many who battle debilitating skin conditions.
Collaboration Leading to Breakthrough Treatment
The journey to ZEVASKYN’s FDA approval is the result of a successful 10-year collaboration between Abeona Therapeutics and Stanford Medicine. Both parties have tirelessly worked towards enhancing patient outcomes for RDEB. This partnership stands as a testament to the dedication of researchers and medical professionals committed to improving the quality of life for patients.
Availability at Qualified Treatment Centers
With the activation of the new Qualified Treatment Center in Stanford, adult and pediatric patients now have access to ZEVASKYN, following the successful start-up activities concluded by the hospital. This center joins the ranks of Lurie Children’s Hospital in Chicago, where ZEVASKYN treatment is already being provided.
Testimonials from Experts
Dr. Madhav Vasanthavada, the Chief Commercial Officer at Abeona, expressed excitement regarding this expansion, stating that this milestone is crucial for commercial launch and patient access. Additionally, Dr. Joyce Teng, a leading dermatologist at Stanford, emphasized the hope this treatment brings to families affected by RDEB, highlighting that ZEVASKYN represents a significant scientific achievement.
Patient Support and Resources
Abeona is deeply committed to ensuring that eligible patients can access ZEVASKYN. Their comprehensive support program, Abeona Assist™, provides essential resources, including assistance with insurance benefits and financial options. Patients can also receive help with travel and logistics to facilitate their treatment journey.
How to Access ZEVASKYN
For those interested in accessing ZEVASKYN or obtaining additional information about the treatment options available, Abeona encourages contacting them directly. Patients can reach out by calling 1-855-ABEONA-1 (1-855-223-6621) or via their support email. Their official website also offers a wealth of information and support services.
Understanding the Safety Profile
As with any medical treatment, ZEVASKYN comes with certain safety considerations. Patients must be aware of potential side effects, including allergic reactions and the risks associated with the gene therapy’s method of action, such as the potential for cancer development. Common side effects include pain from the procedure and itching, though not every patient will experience these effects.
Ongoing Monitoring and Support
It is essential for patients receiving ZEVASKYN to remain in regular contact with their healthcare teams to monitor for any long-term effects or complications. Abeona has set in place measures to ensure that patients have access to report side effects and receive necessary medical advice.
About Abeona Therapeutics
Abeona Therapeutics is a commercial-stage biopharmaceutical company dedicated to innovative cell and gene therapies. Their flagship product, ZEVASKYN™, is unique as the first and only therapy of its kind approved for treating RDEB. In addition to ZEVASKYN, the company is developing AAV-based therapies targeted at various diseases with significant unmet needs.
Frequently Asked Questions
1. What is ZEVASKYN used for?
ZEVASKYN is an autologous gene therapy used to treat wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).
2. How is ZEVASKYN administered?
ZEVASKYN is provided as a single surgical application that modifies the patient’s skin cells to heal wounds and reduce pain.
3. Who can access ZEVASKYN treatment?
Able patients, including adults and children diagnosed with RDEB, are eligible for treatment with ZEVASKYN at certified centers.
4. What safety measures are in place for ZEVASKYN?
Patients will receive comprehensive consultations about potential risks and must continue monitoring for any long-term side effects after treatment.
5. How can patients find more information about ZEVASKYN?
Patients can contact Abeona's support team or visit their website for detailed information regarding access and support options available.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
